

NPASS Inclusion to Pediatric Criteria

MEDITECH PHA 5.6.7

EHR

Update

2026.1

Added N-PASS as an option within Pediatric Admin Criteria v4 Screens

N-PASS Inclusion Update

N-PASS has been added as an additional sedation goal option in the dropdown menu. While not all sites will utilize N-PASS, it is available for facilities that choose to implement it.


For the following medications included in the PED Admin Criteria, N-PASS has been added as an available option for the *Sedation Goal* dropdown:

- Dexmedetomidine
- Fentanyl
- Midazolam (Neonate)
- Propofol

Workflow Example:

N-PASS has been added as an option for Goal: Maintain field. Use the F9 Lookup with the field blank to see all the options.

Screen Sample of Dexmedetomidine:



Enter/Edit Rx's Administration Criteria

Administration Criteria: **Dexmedetomidine PED004**

Initial rate: 0.5 *
Titrate by: 0.2 *
** Maximum rate: 2.5
For maximum rate great Clinical Justification
Goal: Maintain *

Scale: N-PASS,RASS,RAMSAY,SAS Lookup

Select	Mnemonic	Responses
1	N-PASS	N-PASS
2	RAMSAY	RAMSAY
3	RASS	RASS
4	SAS	SAS

<End of list>

OK Cancel Help

Erase Admin Crit
Save as Favorite

mcg/kg/hr

Prev Next



CORP.PharmacyTeam@HCAHealthcare.com

HCA 
Healthcare®

Screen Sample of Fentanyl:

Enter/Edit Rx's Administration Criteria

Administration Criteria: Fentanyl PED04

Initial rate: 1 *
 Titrate by: 0.5 *
 ** Maximum rate: 99
 Goal: ONE goal parameter
 Maintain *
 Maintain pain score
 Goal: *

Scale: N-PASS,RASS,RAMSAY,SAS Lookup

Select

Mnemonic	Responses
1 N-PASS	N-PASS
2 RAMSAY	RAMSAY
3 RASS	RASS
4 SAS	SAS

<End of list>

OK Cancel Help Prev Next

Erase Admin Crit
 Save as Favorite

Screen Sample of Midazolam (Neonate):

Enter/Edit Rx's Administration Criteria

Administration Criteria: Midazolam Neonate PED04 v2

Initial rate: 0.05 * mg/kg
 Titrate by: * mg/kg
 ** Maximum rate: * mg/kg
 Goal: Maintain * of

Scale: N-PASS,RASS,RAMSAY,SAS Lookup

Select

Mnemonic	Responses
1 N-PASS	N-PASS
2 RAMSAY	RAMSAY
3 RASS	RASS
4 SAS	SAS

<End of list>

Prev Next

Erase Admin Crit
 Save as Favorite

Screen Sample of Propofol:

Enter/Edit Rx's Administration Criteria

Administration Criteria: Propofol PED04

Initial rate: 50 * mcg/kg
 Titrate by: 10 * mcg/kg
 ** Maximum rate: 99 mcg/kg
 Goal: Maintain * of

Scale: N-PASS,RASS,RAMSAY,SAS Lookup

Select

Mnemonic	Responses
1 N-PASS	N-PASS
2 RAMSAY	RAMSAY
3 RASS	RASS
4 SAS	SAS

<End of list>

Prev Next

Erase Admin Crit
 Save as Favorite

Hydromorphone Pediatric Admin Criteria

MEDITECH PHA 5.6.7

EHR

Update

2026.1

Hydromorphone Pediatric Admin Criteria Update

The hydromorphone dosing criteria has been updated to improve accuracy in medication calculation and documentation. These changes ensure alignment with current pediatric standards and enhance data entry consistency.

Dosing Unit Changes

No Load Screens

- Previous Unit: **mcg/kg/hr**
- Updated Unit: **mg/kg/hr**

With Load Screen

- **Loading Dose** Field Unit Change:
- Previous Unit: mcg/kg
- Updated Unit: mg/kg
- **Initial Rate and Titrate by** Field Unit Change:
- Previous Unit: **mcg/kg/hr**
- Updated Unit: **mg/kg/hr**

Before and After Comparisons

Dosing unit change from mcg/kg/hr to mg/kg/hr

Screen Samples of No Load Screen – Changing units of measure from **mcg/kg/hr** to **mg/kg/hr**

Enter/Edit Rx's Administration Criteria

Administration Criteria: HYDRORmorphine PED03

Erase Admin Crit
Save as Favorite

Initial rate: * mcg/kg/hr
Titrate by: * mcg/kg/hr every * minutes
Goal: (At least ONE goal parameter is REQUIRED)
Maintain pain score less than
Goal:

Enter/Edit Rx's Administration Criteria

Administration Criteria: HYDRORmorphine PED04 mg

Erase Admin Crit
Save as Favorite

Initial rate: * mg/kg/hr
Titrate by: * mg/kg/hr every * minutes
Goal: (ONE goal parameter is REQUIRED)
Maintain pain score less than or equal to * out of *
Goal:

New Unit Change: mg/kg/hr

Ok Cancel Help Prev Next



CORP.PharmacyTeam@HCAHealthcare.com



Enter/Edit Rx's Administration Criteria

Administration Criteria: HYDROMorphone w Load PED04 mg

Erase Admin Crit
Save as Favorite

Loading dose: mg/kg once over minute(s) (Maximum loading dose: mg)

Initial rate: * mg/kg/hr
Titrate by: * mg/kg/hr every *minutes

Goal: (ONE goal parameter is REQUIRED)
Maintain pain score less than or equal to * out of *
Goal: *

Ok Cancel Help Prev Next

New unit Change: mg/kg

New Unit Change: mg/kg/hr

Fluroquinolone-UTI alert

MEDITECH PHA 5.6.7

EHR

Update

2026.1

Fluroquinolone-UTI alert

Fluroquinolones (FQs) are not first-line therapy for urinary tract infections (UTI) due to significant side effects. These rules introduce alerts to users who select one of two UTI indications from the antibiotic indication (ABXI) screen when entering a FQ order.

The CPOE alert has yes/no buttons and can be bypassed if the provider determines the benefits outweigh the risks.

If an order is entered in Pharmacy, they will receive the same alert at FILE. Users will not see any alerts when verifying orders.

This rule is current for the MEDITECH MAGIC 5.6.7 or later release.

Workflow Examples

Provider Workflow

The provider will select a medication order string from the type-ahead lookup:

Screen Sample – OE order strings

Strings for location: J.PHA

Ciprofloxacin FQ ALERT TESTING (Cipro FQ ALERT TESTING)
PD

Add to Favorites
Monograph
Show All Locations

Dose: 500 Directions: BID PRN: N Start: 10/20 1145 Stop:

Inst: Admin Criteria: MG Taper: Pending: N

After selecting a string and clicking the **<Done>** button, the provider will be presented with the Antibiotic Indication Screen:



CORP.PharmacyTeam@HCAHealthcare.com



Screen Sample - Antibiotic Indication Screen

ABX 4a Gram Negative - POM J00021336189 PETERSON, TEST

Rx Indication:

- Abdominal/Peritoneal Infection
- Bloodstream Infection
- Bone and Joint Infection
- Cardiovascular Infection
- Clostridioides difficile Infection
- CNS Infection
- COPD Exacerbation
- Diarrheal/Gastroenteritis Infection
- Empiric (UNKNOWN Source)
- Neutropenic Fever
- OB/GYN Infection
- OB/GYN Prophylaxis
- Oral/ENT Infection
- Pneumonia-Aspiration
- Pneumonia-Community Acquired
- Pneumonia-Hospital/Ventilator Acqd
- Prophylaxis-Non-Surgical
- Prophylaxis-Surgical
- Sepsis
- Skin & Soft Tissue Infection
- **UTI-Cystitis**
- **UTI-Pyelonephritis/Complicated**
- Other

Gram-negative bacteria have increased resistance to fluoroquinolones.
Avoid empiric use in regions greater than/equal to 10% E.coli resistance.

Rx: Cipro 500 MG PO BID SCH

Rx Indication: *

Other Rx Indication: *

Rx Duration in Days: * Rx Duration in Doses: *

(End)

If the provider selects one of the two highlighted UTI indications, after completing the required fields on the screen and closing it they will receive one of the following alerts based off the indication selected:

UTI – Cystitis:

Screen Sample – Provider FQ UTI Alert

FQ UTI Alert POM DOSE v1

Fluoroquinolones may cause potential permanent and disabling side effects and are not recommended first-line agents for treatment of this indication.

Recommended first-line treatments are (choose one):


- ceftriaxone
- single-dose aminoglycoside (e.g. gentamicin)
- If documented sensitivity: nitrofurantoin (cystitis only) or TMP/SMX

For options based on local susceptibilities and allergies, see institutional guidelines or contact pharmacy.

Click YES to continue this order. Click NO to cancel this order and select a different option.

Yes No


*UTI – Pyelonephritis/Complicated:
Screen Sample – Provider FQ UTI Alert*



If the provider wishes to proceed with the FQ order for the UTI indication, they will select the **<Yes>** button which completes the rule and can proceed with submitting the order.

If the provider no longer wishes to proceed with the FQ order, they will select the **<No>** button which pops a Rule Check screen with a cancel button to complete the cancellation of the order:

Screen Sample – Provider FQ UTI Alert Rule Check



If the provider proceeds with submitting an order after encountering the alert, it will be tracked in the audit trail:

Screen Sample – Audit trail for CPOE order

```

10/27/25 1005 - Rules At Entry                               by DOCHMMW Eff: 10/27/25 1005
CIPR500S: HCA.FQUOE1
CIPR500S: RULE: HCA.FQUOE1
CIPR500S: Fluoroquinolones may cause potential permanent and disabling
           side
CIPR500S: effects and are not recommended first-line agents for treatment
CIPR500S: of this indication.
CIPR500S:
CIPR500S: Recommended first-line treatments are (choose one):
CIPR500S:   - ceftriaxone
CIPR500S:   - single-dose aminoglycoside (e.g. gentamicin)
CIPR500S:   - If documented sensitivity: nitrofurantoin (cystitis only)
           or TMP/SMX
CIPR500S:
CIPR500S: For options based on local susceptibilities and allergies, see
CIPR500S: institutional guidelines or contact pharmacy.
CIPR500S:
CIPR500S: Click YES to continue this order. Click NO to cancel this order
           and
CIPR500S: select a different option.
CIPR500S: User: DOCHMMW
CIPR500S: Yes
  
```

Pharmacy Workflow

There are no alerts seen during verification of an order.

PHA Order Entry

If the pharmacist selects either of the two UTI indications while entering an order in the Pharmacy module, the system will generate the appropriate UTI alert.

Screen Sample – PHA Order Entry Antibiotic Indication Screen

Dispense: 5, INLS, Cart Amount

Inventory: MAIN, MAIN

Charge Type: NOCALC, NOCALAC

Edit Label Comments? ☐

Edit Drug Rx Queries

Rx Indication:

Other Rx Indication:

Rx Duration in Days: Rx Duration


Indications Gram Negative Lookup

Mnemonic	Responses
1 SKIN.INFXN	Skin & Soft Tissue Infxn
2 UTI.COMPLI	UTI-Pyelo/Complicated
3 UTI.CVST	UTI-Cystitis

An alert will be displayed at FILE:

*UTI – Cystitis:
Screen Sample – PHA FQ UTI Alert*

FQ UTI Alert PHA File v1

 **Fluoroquinolones may cause potential permanent and disabling side effects and are not recommended first-line agents for treatment of this indication.**

Recommended first-line treatments are (choose one):


- ceftriaxone
- single-dose aminoglycoside (e.g. gentamicin)
- If documented sensitivity: nitrofurantoin (cystitis only) or TMP/SMX

For options based on local susceptibilities and allergies, see institutional guidelines or contact pharmacy.

Select YES to continue this order. Select NO to return to order entry.

*UTI – Pyelonephritis/Complicated:
Screen Sample – PHA FQ UTI Alert*

FQ UTI Alert PHA File v1

 **Fluoroquinolones may cause potential permanent and disabling side effects and are not recommended first-line agents for treatment of this indication.**

Recommended first-line treatments are (choose one):

- ceftriaxone
- gentamicin

(For penicillin allergy options, see institutional guidelines.)

Select YES to continue this order. Select NO to return to order entry.

If the pharmacist wishes to proceed with filing the order, they will select the <Yes> button which completes the rule and allows filing the order.

If the pharmacist wishes to discard the order, they will select the <No> button which will return them to order entry of this order where they can exit and not enter the order.

NOTE: If the pharmacist proceeds with entering the order after encountering the alert, it will be recorded in the Audit Trail:

Screen Sample – Audit Trail for PHA order

10/27/25 1004 - Rules At Entry	by
	Eff: 10/27/25 1004
CIPR500S:	HCA.FQURX1
CIPR500S:	RULE: HCA.FQURX1
CIPR500S:	Fluoroquinolones may cause potential permanent and disabling side
CIPR500S:	effects and are not recommended first-line agents for treatment of
CIPR500S:	this indication.
CIPR500S:	
CIPR500S:	Recommended first-line treatments are (choose one):
CIPR500S:	- ceftriaxone
CIPR500S:	- single-dose aminoglycoside (e.g. gentamicin)
CIPR500S:	- If documented sensitivity: nitrofurantoin (cystitis only) or TMP/SMX
CIPR500S:	
CIPR500S:	For options based on local susceptibilities and allergies, see
CIPR500S:	institutional guidelines or contact pharmacy.
CIPR500S:	
CIPR500S:	Select YES to continue this order. Select NO to return to order entry.
CIPR500S:	User:
CIPR500S:	Yes

Epoetin Protocol

Rules and screens have been developed to ensure a patient's hemoglobin (Hgb) and blood pressure (BP) are within appropriate limits when epoetin alfa is ordered and administered.

This is achieved by:

- A POM-facing rule that will call an outside-labs screen, if applicable, in addition to an indication screen where a provider will select an indication for the order and then be prompted to enter BP hold parameters, as well as review Hgb hold parameters based on the indication selected.
- A PHA-facing rule that will display POM-alert(s) with override reason(s), if applicable, to the pharmacist for order verification; and that will direct the pharmacist to OM for new order entry.
- A PHA screen will live in the query field of the order and will house the information entered via OM/CPOE.
- An eMAR Admin screen will pop for nursing, on documentation of the medication, and will house the administration parameters for the nurse to review prior to administration.

The project is current for the MEDITECH 5.6.7 or later release.



Workflow Examples

Provider Workflow

The provider will select a medication order string from the type-ahead lookup:

Strings for location: J.PHA

Epoetin Alfa (Epogen)
SUBQ

Add to Favorites
Monograph
Show All Locations

Dose: 10,000 Directions: U PRN: N Start: 01/08 1225 Stop:

Inst: Admin Criteria: Taper: Pending:

** EPOETIN PROJECT TESTING **

After a string is selected, the rule will look for the most recent Hgb value resulted on the patient within the last 7 days, across admissions,

- If a result is found, and is less than 10, the [indication screen](#) will pop for the provider.
- If the most recent Hgb value is greater than or equal to 10, or if no result is found, the provider will receive an additional alert prior to the indication screen.

Hgb Result Greater than or Equal to 10

If the most recent Hgb resulted on the patient is greater than or equal to 10 g/dL, the provider will receive the following alert:

Rule Check: Epoetin Indications - POM

*** PROVIDER PROMPT ***

Last known Hgb greater than or equal to 10 g/dL.
This medication has a boxed warning associated with serious cardiovascular/neurovascular adverse events when targeting Hgb levels exceeding 11 g/dL.

Press Cancel to discard this order.
Press Override to proceed with this order.

Cancel Override Help

- **Cancel** will cancel the order and return the user to the main medication ordering screen.

- **Override** will pop the Override Comment field where the user can either free-text a response or do a <F9> lookup. Once an Override Comment is entered, the ordering provider will be taken to the [indication screen](#).

The image shows two overlapping dialog boxes. The top dialog box, titled "Override Comment Lookup", has a "Select" dropdown menu and a list of options: 1 Emergent Scenario, 2 Baseline Hgb less than 10 g/dL, and 3 Other. A red arrow points from the "Other" option to the "Override Comment for Rule Check" dialog box below it. This second dialog box has a "Comment" field with an information icon (i) to its left. Below the field, it contains the text: "Last known Hgb greater than or equal to 10 g/dL. This medication has a boxed warning associated with serious cardiovascular/neurovascular adverse events when targeting Hgb levels exceeding 11 g/dL. Press Cancel to discard this order. Press Override to proceed with this order." At the bottom are three buttons: "Cancel", "Override", and "Help".

No Recent Hgb Result


If the patient does not have a Hgb value resulted within the last 7 days, the ordering provider will be given the opportunity to input any known result into the Outside Lab screen.

Screen Sample – Outside Lab screen

The image shows a dialog box titled "Epoetin Outside Lab v1a" with a patient ID "J00021636808 EPOETIN,ADULT1". It contains a question "Does patient have a Hgb result in last 7 days?" with two options: 1 Yes and 2 No. Below the options is a yellow highlighted area with the text: "No inpatient Hgb within last 7 days. If patient has a test result from an outside lab, please provide value." At the bottom, there is a question "Does patient have a Hgb result in last 7 days?" followed by an asterisk (*), a field for "Hgb Result Value (g/dL):", and an "(End)" button.

- **No** will pop a Rule Check alert where the provider can choose to Cancel or Override

Screen Sample- Rule Check




Rule Check: Epoetin Indications - POM

*** PROVIDER PROMPT ***

No Hgb documented. Please check Hgb before starting epoetin alfa.
Provide Override Reason to continue.

Press Cancel to discard this order.
Press Override to proceed with this order.

- **Cancel** will cancel the order and return the user to the main medication ordering screen.
- **Override** will pop the Override Comment field where the user can either free-text a response or do a <F9> lookup. Once an Override Comment is entered, the ordering provider will be taken to the [indication screen](#).



Override Comment Lookup

Select

Description

- 1 Emergent Scenario
- 2 Baseline Hgb less than 10 g/dL
- 3 Other

Override Comment for Rule Check

Comment

No Hgb documented. Please check Hgb before starting epoetin alfa.
Provide Override Reason to continue.

Press Cancel to discard this order.
Press Override to proceed with this order.

- **Yes** will advance the cursor to the next query and allow the provider to fill in a value.

Screen Sample – Outside Lab screen

- If the value entered is less than 10, the [indication screen](#) will pop for the provider.
- If the value entered is greater than or equal to 10, the provider will receive the same Rule Check alert outlined in the [“Hgb Result Greater than or Equal to 10” section](#) where they can choose to Cancel or Override.

Indication Screen

If a Hgb value is present and within normal limits, or if the ordering provider has opted to Override either of the previously outlined Rule Check alerts, they will be presented with a screen to select an indication.

Screen Sample – Indication Screen

The **Hgb (g/dL)**, **BP**, and **Rx** fields are “display-only” and cannot be edited.

- **Hgb (g/dL)** will populate with the most recent lab value within the last 7 days, along with the date it was resulted. If the provider filled in a value on the Outside Lab screen, it will NOT populate or be available to view on this screen.
- **BP** will populate with the most recent Blood Pressure documented within the last 24 hours. This field pulls data from the Nursing Vitals Assessment.

If there is no Hgb or BP found in the specified timeframe the respective field will populate with “Not Available”.

The **Rx Indication** and **BP hold parameter** fields are required.

- If Other is selected as the Rx Indication, the “Other Rx Indication” field requires a free-text entry.

Once an indication is selected, the provider is prompted to enter BP hold parameters.

- The **SBP** will pre-populate with a value of 160 but is editable.

Screen Sample – SBP Hold Parameter

The screenshot shows a software window titled "Epoetin Indications - POM" with a patient ID "J00021636819 EPOETIN,ADULT2". The main area contains a calculator for determining when to check blood pressure and hold the dose based on Systolic Blood Pressure (SBP). The calculator has a numeric keypad (0-9, Del, Calc) and a display showing "Check BP and hold dose if SBP greater than (mmHg):". Below the calculator, a yellow box contains the text: "Epoetin alfa is contraindicated in patients with uncontrolled hypertension. Blood pressure threshold of 160/90 mmHg recommendation is based on expert opinion and limited data." At the bottom, there are fields for patient data: "Hgb (g/dL): 8.6 on 01/23/26", "BP: 117/78 on 01/23/26 at 1346", "Rx: EPOGEN 10000 U SUBQ ASDIR SCH", "Rx Indication: Blood Transfusion Risk *", and "Other Rx Indication:". There are also fields for "Check BP and hold dose if SBP greater than (mmHg): 160*" and "Check BP and hold dose if DBP greater than (mmHg): *", with an "(End)" button.

7	8	9	Del
4	5	6	
1	2	3	
	0		Calc

Epoetin alfa is contraindicated in patients with uncontrolled hypertension.
Blood pressure threshold of 160/90 mmHg recommendation is based on expert opinion and limited data.

Hgb (g/dL): 8.6 on 01/23/26 BP: 117/78 on 01/23/26 at 1346
Rx: EPOGEN 10000 U SUBQ ASDIR SCH
Rx Indication: Blood Transfusion Risk *
Other Rx Indication:
Check BP and hold dose if SBP greater than (mmHg): 160*
Check BP and hold dose if DBP greater than (mmHg): * (End) ☐

The **DBP** will pre-populate with a value of 90 but is editable.

Screen Sample - DBP Hold Parameter

The screenshot shows a software window titled "Epoetin Indications - POM" with a patient ID "J00021636819 EPOETIN, ADULT2". At the top, a blue bar contains the text "Check BP and hold dose if DBP greater than (mmHg):". Below this is a numeric keypad with buttons for digits 7-9, 4-6, 1-3, and 0, along with "Del" and "Calc" buttons. A yellow highlighted area contains the text: "Epoetin alfa is contraindicated in patients with uncontrolled hypertension. Blood pressure threshold of 160/90 mmHg recommendation is based on expert opinion and limited data." At the bottom, there are input fields for "Hgb (g/dL): 8.6 on 01/23/26", "BP: 117/78 on 01/23/26 at 1346", "Rx: EPOGEN 10000 U SUBQ ASDIR SCH", "Rx Indication: Blood Transfusion Risk *", and "Other Rx Indication:". Below these are two more input fields: "Check BP and hold dose if SBP greater than (mmHg): 160*" and "Check BP and hold dose if DBP greater than (mmHg): 90 *". An "(End)" button is in the bottom right corner.

Once an indication is selected and the BP hold parameters are filled in the provider will receive a final Rule Check alert outlining when they may be contacted to hold an administration.

Screen Sample – Rule Check

The screenshot shows a modal window titled "Rule Check: Epoetin Indications - POM" with a question mark icon. The text inside reads: "Indication selected: Blood Transfusion Risk", "Hold administration and contact provider if any of the following:", followed by a bulleted list: "- Hgb is less than: 10 g/dL or greater than: 13 g/dL", "- SBP is greater than: 160", and "- DBP is greater than: 90". Below the list, it says "Click Close to proceed with this order." At the bottom are "Close" and "Help" buttons.

This alert is based on the indication selected and the individual BP hold parameters entered by the provider on the Indication screen.


Indication	Hgb hold parameter
CKD on Dialysis	Greater than 11 g/dL
CKD Not on Dialysis	Greater than 10 g/dL
Non-myeloid Malignancy	Greater than 10 g/dL
Myelodysplastic Syndrome	Greater than 10 g/dL
Zidovudine Tx for HIV	Greater than 10 g/dL
Blood Transfusion Risk	Less than 10 g/dL or greater than 13 g/dL
Other	Greater than 10 g/dL

The provider will review and click Close to proceed.

Any alert and associated Override Comment, if applicable, will be logged to the audit trail for the medication order and will be viewable in the Print Order.

At any point during the ordering process, if the provider chooses to exit the Outside Lab screen or the Indication Screen using <F11>, closure through <X> or <Esc> key, they will receive the following Rule Check alert.

Screen Sample – Cancel Rule Check



Clicking Cancel will take the provider back to the main medication ordering field.


Pharmacist Workflow

Order Verification

As the pharmacist processes through order verification, a Y/N alert will fire for the pharmacist at the DOSE field. The alert details the indication selected by the ordering provider, as well as any prompts that the provider received and associated Override Comment(s), if applicable.

Screen Sample – Indication and Hold Parameters Only

Epoetin Alert



Indication selected by provider:
CKD on Dialysis


Prompt presented to provider:
Hold administration and contact provider if any of the following:

- Hgb is greater than: 11 g/dL
- SBP is greater than: 160
- DBP is greater than: 90

Have you reviewed the above information?

Screen Sample – Alert Plus Override

Epoetin Alert



Indication selected by provider:
Blood Transfusion Risk

Prompt presented to provider:
Last known Hgb greater than or equal to 10 g/dL.
This medication has a boxed warning associated with serious cardiovascular/neurovascular adverse events when targeting Hgb levels exceeding 11 g/dL.

Override Comment:
Baseline Hgb less than 10 g/dL

Hold administration and contact provider if any of the following:


- Hgb is less than: 10 g/dL or greater than: 13 g/dL
- SBP is greater than: 160
- DBP is greater than: 90

Have you reviewed the above information?

Clicking either Yes or No will allow the pharmacist to proceed with order verification, and the response will be logged in the Audit Trail of the Print Order.

At any point during verification, the pharmacist can access the Query field on the order to see what was entered by the ordering provider.

Screen Sample – Query Field (Order Entry CDS)



Edit Drug Rx Queries

Does patient have a Hgb result in last 7 days? ☐

Hgb Result Value (g/dL):

Hgb (g/dL): 10.2 on 01/05/26 BP: 117/78 on 01/08/26 at 1325

Rx Indication: Blood Transfusion Risk

Other Rx Indication:

Check BP and hold dose if SBP greater than (mmHg): 160

Check BP and hold dose if DBP greater than (mmHg): 90

(End) ☐

Order Entry

After the pharmacist selects a drug mnemonic, a hard-stop alert will fire directing them to Order Entry through OM.

Screen Sample – Hard Stop at MED



Epoetin Alert

 In order to ensure appropriate screening, this medication requires order entry through OM with provider-selected parameters.


Ok

They must click Ok, then select <F10> to clear the med mnemonic field before they can back out of the order entry screen.

Nurse Workflow

As the nurse documents on the medication order, the eMAR Admin screen will pop:

Screen Sample – MAR Admin screen



Administration Queries

*** Administration parameters ***

Hold dose and contact provider if any of the following:

Hgb is greater than (g/dL): 11

Hgb is less than (g/dL):

SBP is greater than (mmHg): 160

DBP is greater than (mmHg): 90

Most recent Hgb (g/dL): 9.8 on 01/09/26

All queries are display-only and for informational purposes.

- All the hold parameters populate based on what was entered by the ordering provider.
- The most recent Hgb, from within the last 7 days, will populate the last field.

After reviewing the alert, the nurse can proceed with medication documentation.

Dispensing Machine Audit Report (DMAR)

MEDITECH 5.6.7 PHA Update

EHR

Update

2026.1

Dispensing Machine Audit Report (DMAR) Update for 2026.1 Release

The Dispensing Machine Audit Report is intended to help reconcile medications removed from an automated dispensing cabinet and to verify they were administered to a patient.


This report serves as a medication safety tool, lost charge reconciliation tool, and a medication diversion deterrent.

Workflow Examples:

The output for when the report returns no records has been updated to include run information and to better align with the report output when records are found.

- If the report is run with valid dates and times (i.e., the run parameters are within the NMI purge parameter window), but there are no dispense/administration events that match the run parameters provided, the output will show “No records found” but will also display a header that shows the Run Parameters used, as well as the Run Date, Run Time, and Run User.

Screen  ple -No records found.



The screenshot displays the DMAR output for a run on 11/20/25 at 1531. The header includes the run date, time, and user, along with the report title "KYA QAI PHA **TEST** Dispensing Machine Audit (Version 2026)". The run parameters are listed: Locations: ALL, Users: ALL, From Date: 11/18/25 Time: 0000 Thru Date: 11/20/25 Time: 2359, All Dispenses: Y, Controlled: C, Medications: ALL, and Print Audit History: Y. The main body of the report shows "No records found." and the report name "PHA.RX.scus.hca.disp.machine.audit.0081.v2026.1".

```
RUN DATE: 11/20/25
RUN TIME: 1531
RUN USER:
KYA QAI PHA **TEST**
Dispensing Machine Audit (Version 2026)
Locations: ALL Users: ALL From Date: 11/18/25 Time: 0000 Thru Date: 11/20/25 Time: 2359 All Dispenses: Y Controlled: C Medications: ALL Print Audit History: Y
No records found.
Report Name: PHA.RX.scus.hca.disp.machine.audit.0081.v2026.1
```

- If the report is run with any date parameter outside of the NMI purge parameter window, and therefore the HL7 messages have already been purged from MEDITECH, the output will show “Date Range entered is beyond first available Dispensing Machine dispense date: mm/dd/yy”. The report will also display a header that shows the Run Parameters used, as well as the Run Date, Run Time, and Run User.



CORP.PharmacyTeam@HCAHealthcare.com



Screen Sample – Date Range entered is beyond first available Dispensing Machine dispense date

RUN DATE: 11/18/25
RUN TIME: 0938
RUN USER: [REDACTED]

KYA QAL PHA **TEST**
Dispensing Machine Audit (Version 2026)

Locations: ALL Users: ALL From Date: 10/19/25 Time: 0000 Thru Date: 10/19/25 Time: 2359 All Dispenses:Y Controlled:C Medications: ALL Print Audit History:Y

Date Range entered is beyond first available Dispensing Machine dispense date: 11/04/25

No records found

Report Name: PHA.RX.zcus.hca.disp.machine.audit.0081.v2026.1

Cervidil Screen and Rule Update

MEDITECH PHA 5.6.7

EHR

Update

2026.1

Cervidil Screen and Rule Update

HCA Healthcare has developed screens and rules to assist in ordering efforts of the cervical ripening agent Cervidil (generic name dinoprostone).

A POM-facing rule will require providers to select criteria for use of Cervidil and to attest that a checklist of items have been documented in the chart to support this selection.

During order verification, the PHA-facing rule will display the criteria selected, the alerts shown to the provider, and the provider's responses to any queries.

During pharmacy order entry, the PHA-facing rule will require the pharmacist to select criteria for use. The provider attestation will NOT be captured during PHA order entry.

This project is current for MEDITECH 5.6.7 or later release.

Workflow Examples

Provider Workflow

The provider will select a medication order string from the type-ahead lookup:

Screen Sample

Strings for location: J.PHP

Dinoprostone (Cervidil Supp)
VAGINAL

Add to Favorites
Monograph
Show All Locations

Dose: [dropdown] Directions: [dropdown] PRN: [dropdown] Start: 11/25 1105 [dropdown] Stop: [dropdown]

Inst: [dropdown] Admin Criteria: [dropdown] Taper: [dropdown] Pending: [dropdown]

10 M6 Q12H N

After a string is selected, the rule will display the POM screen, and a criteria selection will be required.



CORP.PharmacyTeam@HCAHealthcare.com



Cervidil - POM v1a

Criteria for Cervidil use:

- 1 Fetal Growth Restriction (less than 10% estimated fetal weight)
- 2 Oligohydramnios
- 3 Prolonged pregnancy (\geq 42 weeks)
- 4 Other

Please select the appropriate criteria.

Criteria for Cervidil use: *

Other criteria:

Rx indication: Cervical ripening

NOTE: The “Rx indication:” query will auto-populate with “Cervical ripening” and will not be accessible or editable.

Criteria Selection (Non-Other)

Once the user selects a criterion (from either the Point-n-Click screen or <F9> lookup), they will be presented with page 2 of the POM screen.

On page 2, the checklist attestation (“All items listed...” query) is required.

Answering query with Yes will complete the screen.

Answering this query with No will require a free-text entry in the “If no, why:” query.

Cervidil - POM v1a

All items listed are documented in the patient chart:

- 1 Yes
- 2 No

If checklist cannot be completed and all items are not documented in chart, oxytocin or cervical ripening should not be initiated.

- Indication for induction/augmentation/cervical ripening documented in chart
- Pelvis is documented by provider to be clinically adequate for vaginal delivery
- Estimated fetal weight is less than 5000 grams in non-diabetic patient (4500 grams for diabetic)
- Gestational age documented
- Provider with C-Section privileges is aware of the induction and readily available
- Status of cervix is assessed and documented, including all elements of Bishop score
- Presentation is assessed and documented as cephalic

Criteria for Cervidil use: Fetal Growth Restriction

All items listed are documented in the patient chart: *

If no, why:

(End) ☐

Once all required queries are completed, the provider may submit the order.

Screen Sample – hcarx.CERVPv1a Page 2 Free Text

The screenshot shows a window titled "Cervidil - POM v1a". Inside, there is a blue header bar with the text "If no, why:". Below this, there is a large text area with the prompt "Enter free text." and "Word wrap allowed.". At the bottom of the window, there is a section for "Criteria for Cervidil use:" with a dropdown menu showing "Fetal Growth Restriction". Below the dropdown, there is a text field with the prompt "All items listed are documented in the patient chart:" and a dropdown menu showing "N". To the right of this field is an asterisk "*". Below the text field, there is a message: "If no, why: THIS FREE TEXT FIELD IS NOW REQUIRED. IT SUPPORTS MULTI-LINE FREE TEXT AND WORD WRAP." and an "(End)" button.

Criteria Selection (“Other”)


If Other is selected for the criteria, the following Yes/No confirmation will display.

Screen Sample- Yes/No Confirmation

The screenshot shows a dialog box titled "Yes/No Confirmation". Inside, there is a question mark icon and the text: "If Cervidil exceptions are not met, use alternative options including single mechanical methods (foley, cook), misoprostol, or combination methods." Below this text, there is a "Continue?" prompt and two buttons: "Yes" and "No".


No will display the following Message, then the Rule Check screen and allow the user to cancel the order.

Screen Sample – Continue to Cancel Message




NOTE: This is a system message due to cancelling the order, which results in a two-page screen and is not part of the project programming. Currently this is unavoidable.

Screen Sample – Cancel Message



Yes will allow the user to continue placing the order and the “Other criteria:” query will be required.

Screen Sample – “Other criteria:” Query Is Now Required



On page 2, the checklist attestation (“All items listed...” query) is still required. Answering this query with **Yes** will complete the screen. Answering this query with **No** will require a free-text entry in the “If no, why:” query.

Screen Sample

The screenshot shows a software window titled "Cervidil - POM v1a". At the top, a blue bar contains the text "All items listed are documented in the patient chart:". Below this, a list of criteria is displayed in a yellow box:

- 1 Yes
- 2 No

If checklist cannot be completed and all items are not documented in chart, oxytocin or cervical reipening should not be initiated.

- Indication for induction/augmentation/cervical ripening documented in chart
- Pelvis is documented by provider to be clinically adequate for vaginal delivery
- Estimated fetal weight is less than 5000 grams in non-diabetic patient (4500 grams for diabetic)
- Gestational age documented
- Provider with C-Section privileges is aware of the induction and readily available
- Status of cervix is assessed and documented, including all elements of Bishop score
- Presentation is assessed and documented as cephalic

Criteria for Cervidil use: FREE TEXT RESPONSE GOES HERE

All items listed are documented in the patient chart: ☐

If no, why: *

(End)

Screen Sample – Required Explanation Query

The screenshot shows the same software window, but now the "If no, why:" section is active. The text "If no, why:" is highlighted in a blue bar. Below it, the text "Enter free text. Word wrap allowed." is displayed. The criteria for Cervidil use are still visible at the bottom.

Criteria for Cervidil use: FREE TEXT RESPONSE GOES HERE

All items listed are documented in the patient chart: ☐

If no, why: THE PROVIDER CAN ENTER A FREE TEXT RATIONALE IN THIS MULTI-LINE QUERY WITH WORD WRAP *

(End)

After completing all required queries, the provider will be able to submit the order.

Pharmacy Workflow

PHA Order Verification

DOSE

As the pharmacist processes through verification, a Y/N alert will fire for the pharmacist at the DOSE field. The alert details the criteria selected by the ordering provider, as well as the prompts that the provider received, and any other free-text information entered by the provider.

Screen Sample – PHA DOSE Alert

Cervidil Alert

Criteria selected by provider:
Fetal Growth Restriction

Indication selected by provider:
Cervical ripening

Prompt presented to provider:
If checklist cannot be completed and all items are not documented in chart, oxytocin or cervical ripening should not be initiated.

- Indication for induction/augmentation/cervical ripening documented in chart
- Pelvis is documented by provider to be clinically adequate for vaginal delivery
- Estimated fetal weight is less than 5000 grams in non-diabetic patient (4500 grams for diabetic)
- Gestational age documented
- Provider with C-section privileges is aware of induction and readily available
- Status of cervix is assessed and documented, including all elements of Bishop score
- Presentation is assessed and documented as cephalic

All items listed are documented in the patient chart: No

SOME FREE TEXT REASON WOULD GO HERE

Have you reviewed the above information?

Yes is required for the pharmacist to proceed with processing the order, including **PENDING** the order. **No** will allow them to back out of the order.

The criteria selected, query responses, and alerts that fire for the pharmacist during Order Verification or Entry, along with the associated answers, will be logged in the audit trail for the medication order, and viewable in the Print Order.

Screen Sample – Query Responses in the Audit Trail

```
Criteria for Cervidil use: Fetal Growth Restriction
Other criteria:
Rx indication: Cervical ripening
All items listed are documented in the patient chart: N
If no, why: SOME FREE TEXT REASON WOULD GO HERE
Criteria for Cervidil use:: Fetal Growth Restriction
```

Screen Sample – Alert Text in the Audit Trail

```
12/10/25 1219 - Rules At Edit by [REDACTED]
CERUSUPP:
CERUSUPP: Criteria selected by provider:
CERUSUPP: Fetal Growth Restriction
CERUSUPP:
CERUSUPP: Indication selected by provider:
CERUSUPP: Cervical ripening
CERUSUPP:
CERUSUPP: Prompt presented to provider:
CERUSUPP: If checklist cannot be completed and all items are not
CERUSUPP: documented in chart, oxytocin or cervical ripening should not
CERUSUPP: be
CERUSUPP: initiated.
CERUSUPP: - Indication for induction/augmentation/cervial ripening
CERUSUPP: documented in chart
CERUSUPP: - Pelvis is documented by provider to be clinically adequate
CERUSUPP: for
CERUSUPP: vaginal delivery
CERUSUPP: - Estimated fetal weight is less than 5000 grams in
CERUSUPP: non-diabetic
CERUSUPP: patient (4500 grams for diabetic)
CERUSUPP: - Gestational age documented
CERUSUPP: - Provider with C-section privileges is aware of induction and
CERUSUPP: readily available
CERUSUPP: - Status of cervix is assessed and documented, including all
```

```
CERUSUPP: elements of Bishop score
CERUSUPP: - Presentation is assessed and documented as cephalic
CERUSUPP: All items listed are documented in the patient chart: No
CERUSUPP:
CERUSUPP: SOME FREE TEXT REASON WOULD GO HERE
CERUSUPP:
CERUSUPP: Have you reviewed the above information?
CERUSUPP: User: [REDACTED]
CERUSUPP: Yes
```

PHA Order Entry

Order Entry CDS

The criteria fields within the Order Entry CDS will be required prior to filing the new medication order as verified.

Screen Sample – PHA CDS Attached at Query Field

Med CERUSUPP
(Med,Dose,Route,Sig,Schedule,Par,PRN Reason,Total Doses)
DINOPROSTONE 10 MG SUPP,VAG
(Rx ID <P
Clinical In
Dose
Route
Sig
Schedule
Start Date
Stop Date 12/10/23 Stop time 12:20 Soft Stop
Inventory MAIN MAIN
Charge Type NOCALC NOCALAC Charge 0.00 (PER DOSE)
Edit Label Comments? ☐
Rx Cmnts ☐ E ☒ Query ☒ E ☒
Prep Instr ☐ E ☐ Output ☐ E
Spec Instr ☐ E ☐ NF Qry ☒ V
Admin Crit ☐ E ☐ Pend ☐ E
Lot/Dur/Exp ☐ E

The pharmacist can select a criterion via <F9> lookup. Like the provider workflow, if “Other” is selected, the “Other criteria:” query will be required.

Screen Sample

Edit Drug Rx Queries
Criteria for Cervidil use: Other *
Other criteria: SOME OTHER FREE TEXT CRITERIA *
Rx indication: Cervical ripening
All items listed are documented in the patient chart: ☐ *
If no, why: ☐ *

NOTE: when entering a new order from PHA, the provider attestation queries will NOT be required, but will still be accessible to the pharmacist.

The criterion selected, query responses, and alerts that fire for the pharmacist during Order Verification or Entry, along with the associated answers, will be logged in the audit trail for the medication order, and viewable in the Print Order.

Screen Sample – Query Responses in the Audit Trail

```
Criteria for Cervidil use: Fetal Growth Restriction
Other criteria:
Rx indication: Cervical ripening
All items listed are documented in the patient chart: N
If no, why: SOME FREE TEXT REASON WOULD GO HERE
Criteria for Cervidil use:: Fetal Growth Restriction
```

Screen Sample – Alert Text in the Audit Trail

```
12/10/25 1219 - Rules At Edit by [REDACTED]
CERUSUPP:
CERUSUPP: Criteria selected by provider:
CERUSUPP: Fetal Growth Restriction
CERUSUPP:
CERUSUPP: Indication selected by provider:
CERUSUPP: Cervical ripening
CERUSUPP:
CERUSUPP: Prompt presented to provider:
CERUSUPP: If checklist cannot be completed and all items are not
CERUSUPP: documented in chart, oxytocin or cervical ripening should not
CERUSUPP: be
CERUSUPP: initiated.
CERUSUPP: - Indication for induction/augmentation/cervical ripening
CERUSUPP: documented in chart
CERUSUPP: - Pelvis is documented by provider to be clinically adequate
CERUSUPP: for
CERUSUPP: vaginal delivery
CERUSUPP: - Estimated fetal weight is less than 5000 grams in
CERUSUPP: non-diabetic
CERUSUPP: patient (4500 grams for diabetic)
CERUSUPP: - Gestational age documented
CERUSUPP: - Provider with C-section privileges is aware of induction and
CERUSUPP: readily available
CERUSUPP: - Status of cervix is assessed and documented, including all
```

```
CERUSUPP: elements of Bishop score
CERUSUPP: - Presentation is assessed and documented as cephalic
CERUSUPP: All items listed are documented in the patient chart: No
CERUSUPP:
CERUSUPP: SOME FREE TEXT REASON WOULD GO HERE
CERUSUPP:
CERUSUPP: Have you reviewed the above information?
CERUSUPP: User: [REDACTED]
CERUSUPP: Yes
```

Balfaxar Screen Update for Supplemental Dose

MEDITECH PHA 5.6.7

EHR
Update
2026.1

Balfaxar Screen Update for Supplemental Dose

The Supplemental Dosing Screen has been updated. Prior to the update, an ordering provider could bypass the **500 units** or **1000 units** Y/N queries and click into the **Approx. Dose:** field, entering any number.

The Screens were updated to require a Y in either the **500 units** or **1000 units** queries. In addition, the **Approx. Dose:** and **Number of vials (Kits):** fields were made inaccessible to prevent a free-texted number.

Workflow Examples

Provider Workflow Scenarios

Supplemental Dose

The patient's most recent INR value from their current stay will populate the **INR:** query along with the date and time it was resulted.

Screen Sample -Admin Criteria

The screenshot shows the 'Enter/Edit Rx's Administration Criteria' window for Balfaxar supplemental dosing. The 'Administration Criteria' dropdown is set to 'Balfaxar supplemental dosing'. The 'Balfaxar Dosing' section contains the following fields:

- Indication: Supplemental dosing for life threatening bleed
- INR: 5.1 01/24/2024 0951 H (highlighted with a red box and arrow)
- Extra dose (Y/N): 500 units ☐ OR 1,000 units ☐
- Approx. Dose: units
- Number of vials (Kits):

A note at the bottom states: 'NOTE: Each vial can contain 400-640 units of Balfaxar. Administered dose will vary. Provider will be queued for signature of administered dose.'

Buttons at the bottom include 'Ok', 'Cancel', 'Help', 'Prev', and 'Next'.



CORP.PharmacyTeam@HCAHealthcare.com



The provider is required to put a Y next to either the **500 units** or **1,000 units** query. If they attempt to leave both blank or answered with N, the provider will receive an Error:

Screen Sample: Error if 500 units and 1,000 units are answered N

The screenshot shows the 'Enter/Edit Rx's Administration Criteria' window. The 'Administration Criteria' dropdown is set to 'Balfaxar supplemental dosing'. The 'Balfaxar Dosing' section displays 'Indication: Supplemental dosing for life threatening bleed' and 'INR: 5.1 01/24/2024 0951 H'. Below this, the 'Extra dose (Y/N): 500 units ☐ OR 1,000 units ☐ *' is shown. A red box highlights this field, and a red arrow points to it. An error dialog box is open, titled 'Error', with the message 'Select 'Y' to indicate which extra dose is needed.' and an 'Ok' button. The main window has buttons for 'Erase Admin Crit', 'Save as Favorite', 'Ok', 'Cancel', 'Help', 'Prev', and 'Next'.

Screen Sample: Error if attempted to leave both BLANK

The screenshot shows the 'Enter/Edit Rx's Administration Criteria' window. The 'Administration Criteria' dropdown is set to 'Balfaxar supplemental dosing'. The 'Balfaxar Dosing' section displays 'Indication: Supplemental dosing for life threatening bleed' and 'INR: 5.1 01/24/2024 0951 H'. Below this, the 'Extra dose (Y/N): 500 units ☐ OR 1,000 units ☐ *' is shown. A red box highlights this field, and a red arrow points to it. An error dialog box is open, titled 'Error', with the message 'This is a required field!' and an 'Ok' button. The main window has buttons for 'Erase Admin Crit', 'Save as Favorite', 'Ok', 'Cancel', 'Help', 'Prev', and 'Next'.

Entering a **Y** next to the **500 units** query will populate the **Approx. Dose:** query with **500**.

Entering a **N** or Pressing **<Enter>** in the **500 units** query will move the cursor to the **1,000 units** query. Entering a **Y** here will populate the **Approx. Dose:** query with **1000**.

When the cursor lands on the **Number of vials (Kits):** query, it will autopopulate with **1** or **2** for **Approx. Dose** of **500** or **1000** respectively. The Admin Criteria is then ready to file.

Screen Sample:

Enter/Edit Rx's Administration Criteria

Administration Criteria Balfaxar supplemental dosing

Erase Admin Crit

Save as Favorite

Balfaxar Dosing

Indication: Supplemental dosing for life threatening bleed

INR: 5.1 01/24/2024 0951 H

Extra dose (Y/N): 500 units Y OR 1,000 units *

Approx. Dose: 500 units Number of vials (Kits): 1

NOTE: Each vial can contain 400-640 units of Balfaxar. Administered dose will vary.
Provider will be queued for signature of administered dose.

Ok Cancel Help Prev Next

As the **Approx. Dose:** query and the **Number of vials (Kits):** query auto-populate based on previous query answers, they are inaccessible for editing.

Adult Vasopressin Admin Criteria Updates

MEDITECH PHA 5.6.7

EHR

Update

2026.1

Adult Vasopressin Admin Criteria Updates

Currently, there are two Admin Criteria recommendations for vasopressin with specific indications: GI Bleed and Shock. To align with MEDITECH Expanse standards, vasopressin will have two additional screens for non-specific indications, featuring titratable rate options measured in units/hr and units/min. These new screens will increase the options of vasopressin orders for providers and pharmacists, as well as align with the Expanse Cloud workflow.

Screen Updates

Screen Shot – Units/Hour

Enter/Edit Rx's Administration Criteria

Administration Criteria: Vasopressin units/hr ADLT05

Erase Admin Crit
Save as Favorite

Initial rate: * units/hour
Titrate by: * units/hour every 10* minute(s)
** Maximum rate: * units/hour **

Goal: (ONE goal parameter is REQUIRED)
Maintain SBP between * - * mmHg
Maintain MAP greater than * mmHg
Goal: *

Ok Cancel Help Prev Next



CORP.PharmacyTeam@HCAHealthcare.com

HCA 
Healthcare®

Screen Shot – Units/Minute

Enter/Edit Rx's Administration Criteria

Administration Criteria: Vasopressin units/min ADLT05

Erase Admin Crit
Save as Favorite

Initial rate: * units/minute
Titrate by: * units/minute every * minute(s)
** Maximum rate: * units/minute **

Goal: (ONE goal parameter is REQUIRED)
Maintain SBP between * - * mmHg
Maintain MAP greater than * mmHg
Goal: *

Ok Cancel Help Prev Next